ENTITY

Oncopeptides (ONCO SS)

18
Analysis
Health Care • Sweden
Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.
more
Company Event • 05 Nov 2026 16:00 • Upcoming
Add To Calendar

Q3 2026

Company Event • 18 Feb 2027 16:00 • Upcoming
Add To Calendar

Q4 2026

Company Event • 12 Oct 2026 14:00 • Latest

Study update

Company Event • 27 Aug 2026 15:00

Q2 2026

Company Event • 09 Jun 2026 14:25

Aktiedagarna 2026

x